Quarterly report pursuant to Section 13 or 15(d)

INTERIM FINANCIAL STATEMENTS (Details)

v3.4.0.3
INTERIM FINANCIAL STATEMENTS (Details) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and liquid investments $ 16,600,000  
Working capital 16,183,000  
Stockholders' equity 16,678,031 $ 16,070,636
Accumulated deficit 105,022,928 $ 105,582,439
Total value of capitalized patent costs that could be impaired due to inability to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio $ 374,000